Context Therapeutics

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Context Therapeutics is dedicated to discovering and developing therapies to target the underlying causes of complex diseases and delivering them to patients around the world.

Context Therapeutics’s vision is to become the global leader in developing innovative therapies designed to improve the lives of people suffering from complex diseases of the central nervous system and endocrine disorders.

Context Therapeutics has won numerous awards, including the Nobel Prize in Medicine , the National Academy of Sciences Achievement Award and the American Society of Biochemistry and Molecular Biology Laureate Award .